Treating chronic cough and breathlessness by an antibiotic

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Registration Number: CTRI/2011/07/001897

Lead Sponsor: Dr Parthasarathi Bhattacharyya

Brief Summary: **In this open,real world prospective observation we wish to see the effect of long term use of oral doxycycline (100 mg BD)on the lung function of a cohort of stable advanced COPD patients. The follow up and the performance of the repeat spirometry were left totally to the patients convenience as it actually happens in real world practice.**

**We have the initial data being collected from 28 patients of COPD (Mean FEVI 0.82±0.32 post bronchodialator ) shows improvement in FEVI to a of about 90 ml in post bronchodialator.**

**They received the medication for about 735±442 days.**

**This is no way a conventional drug trial .A molecule available over 30 yrs in the market with well known details of tolerance of long term use in other indications has been used in a real world practice to observe its effects on lung function of COPD patients.**

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 30

Inclusion Criteria

Informed written consent being given Male and female patients aged 40-70 years Has been on optimum pharmacotherapy for COPD COPD severity diagnosed by GOLD criteria No significant occupational history FEVI 30-50%predicted; FEVI/FVC less than70% Non pregnant, non lactating woman.

Exclusion Criteria

History of exacerbation in past 1 month History of Doxy allergy Having any obvious contraindication for Doxycycline Unable to meet the demand of the protocol for any reason Significant abnormality in liver or renal or other organ function Feature of chronic congestive cardiac failure (supported by echocardiography any other concomitant lung disease (significant as per PI).

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
change in both pre and post bronchodilator FEVI	As and when atleast 30 patients will take doxycycline for at least 6 months and shall have at least one repeat spirometry done in a real world situation.

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (1): Institute of Pulmocare& Research
🇮🇳
Kolkata, WEST BENGAL, India
Institute of Pulmocare& Research
🇮🇳Kolkata, WEST BENGAL, India
Dr Parthasarathi Bhattacharyya
Principal investigator
03323580424
pathachest@yahoo.com